\[[PubMed: 32568052](https://pubmed.ncbi.nlm.nih.gov/32568052)\] 64. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 01;200(7):e45-e67. \[[PMC free article: PMC6812437](/pmc/articles/PMC6812437/)\] \[[PubMed: 31573350](https://pubmed.ncbi.nlm.nih.gov/31573350)\] 65. Garin N, Marti C, Skali Lami A, Prendki V. Atypical Pathogens in Adult Community-Acquired Pneumonia and Implications for Empiric Antibiotic Treatment: A Narrative Review. Microorganisms. 2022 Nov 24;10(12) \[[PMC free article: PMC9783917](/pmc/articles/PMC9783917/)\] \[[PubMed: 36557579](https://pubmed.ncbi.nlm.nih.gov/36557579)\] 66. Liu X, Ma J, Huang L, Zhu W, Yuan P, Wan R, Hong K. Fluoroquinolones increase the risk of serious arrhythmias: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Nov;96(44):e8273. \[[PMC free article: PMC5682775](/pmc/articles/PMC5682775/)\] \[[PubMed: 29095256](https://pubmed.ncbi.nlm.nih.gov/29095256)\] 67. Piso RJ, Arnold C, Bassetti S. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters. Swiss Med Wkly. 2013;143:w13870. \[[PubMed: 24089030](https://pubmed.ncbi.nlm.nih.gov/24089030)\] 68. Reyes LF, Bastidas AR, Quintero ET, Frías JS, Aguilar ÁF, Pedreros KD, Herrera M, Saza LD, Nonzoque AP, Bello LE, Hernández MD, Carmona GA, Jaimes A, Ramírez SM, Murillo N. Performance of the CORB (Confusion, Oxygenation, Respiratory Rate, and Blood Pressure) Scale for the Prediction of Clinical Outcomes in Pneumonia. Can Respir J. 2022;2022:4493777. \[[PMC free article: PMC9187474](/pmc/articles/PMC9187474/)\] \[[PubMed: 35692950](https://pubmed.ncbi.nlm.nih.gov/35692950)\] 69. Memon RA, Rashid MA, Avva S, Anirudh Chunchu V, Ijaz H, Ahmad Ganaie Z, Kabir Dar A, Ali N. The Use of the SMART-COP Score in Predicting Severity Outcomes Among Patients With Community-Acquired Pneumonia: A Meta-Analysis. Cureus. 2022 Jul;14(7):e27248. \[[PMC free article: PMC9409612](/pmc/articles/PMC9409612/)\] \[[PubMed: 36043007](https://pubmed.ncbi.nlm.nih.gov/36043007)\] 70. Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, Sturgeon K, Finn A, Rodriguez-Ruiz JP, Malhotra-Kumar S, Powell C, Faust SN, Alcock AE, Hall D, Robinson G, Hawcutt DB, Lyttle MD, Gibb DM, Sharland M., PERUKI, GAPRUKI, and the CAP-IT Trial Group. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021 Nov 02;326(17):1713-1724. \[[PMC free article: PMC8564579](/pmc/articles/PMC8564579/)\] \[[PubMed: 34726708](https://pubmed.ncbi.nlm.nih.gov/34726708)\] 71. Linz DH, Tolle SW, Elliot DL. Mycoplasma pneumoniae pneumonia. Experience at a referral center. West J Med. 1984 Jun;140(6):895-900. \[[PMC free article: PMC1011124](/pmc/articles/PMC1011124/)\] \[[PubMed: 6741120](https://pubmed.ncbi.nlm.nih.gov/6741120)\] 72. Reittner P, Müller NL, Heyneman L, Johkoh T, Park JS, Lee KS, Honda O,